Regeneron Pharmaceuticals is trading at $934.08, down -4.04%, with no clear company-specific explanation identified for the November 4 decline. - Available coverage highlighted the October 30 earnings beat and subsequent analyst target increases; neither explains the decline. - The move runs counter to the provided broader-market and biotech strength, so those trends do not explain it. - Trading volume or another direct catalyst was not established in the available evidence.